This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.
Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
-
Phoenix VA Healthcare System, Phoenix, Arizona, United States, 85012-1839
Homestead Associates in Research, Inc., Miami, Florida, United States, 33032
Advanced Discovery Research, Atlanta, Georgia, United States, 30318
Tripler Army Medical Center (TAMC), Tripler AMC, Hawaii, United States, 96859
Cincinnati Veteran's Affairs Medical Center, Fort Thomas, Kentucky, United States, 41075
Upstate Clinical Research Associates, LLC, Williamsville, New York, United States, 14221
Wilford Hall Ambulatory Surgical Center (WHASC), San Antonio, Texas, United States, 78236
Madigan Army Medical Center, Joint Base Lewis McChord, Washington, United States, 98433
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 65 Years
ALL
Yes
Global Coalition for Adaptive Research,
2026-09